Quarterly ResultApr 28, 2026, 07:30 AM
WVE Q1 Revenue $38.2M; Cash $544.6M; Pipeline Progress
AI Summary
Wave Life Sciences Ltd. announced Q1 2026 financial results, reporting $38.2 million in revenue and a net loss of $26.1 million. The company maintains a strong financial position with $544.6 million in cash and equivalents, providing a runway into Q3 2028. Significant pipeline progress includes FDA acceptance for the WVE-007 Phase 2a INLIGHT trial, upcoming data presentations for WVE-006, and a CTA filing for WVE-008, all on track for 2026.
Key Highlights
- Cash and cash equivalents were $544.6 million as of March 31, 2026.
- Expected cash runway into Q3 2028.
- Q1 2026 Revenue was $38.2 million, up from $9.2 million YoY.
- Q1 2026 Net Loss was $26.1 million, an improvement from $46.9 million YoY.
- WVE-007 Phase 2a INLIGHT trial initiation on track for Q2 2026.
- WVE-006 RestorAATion-2 data (400mg, 600mg cohorts) to be presented in May 2026.
- WVE-006 regulatory feedback on accelerated approval pathway expected mid-2026.
- WVE-008 CTA filing on track for 2026.